Navigation Links
Varespladib Receives 2010 European Society Pediatric Research Award
Date:12/7/2010

HAYWARD, Calif., Dec. 7, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced that their product candidate varespladib (A-001) was awarded the 2010 European Society Pediatric Research Award at the Third Congress of the European Academy of Pediatric Societies 2010 in Copenhagen, Denmark where Dr. Daniele De Luca, MD, PhDst at the University Pope's Hospital and the Pediatric Intensive Care Unit at the Catholic University of Sacred Heart in Rome, presented their study "New Anti-inflammatory Therapy for Neonatal Acute Lung Injury: Varespladib (A-001) Inhibits Ex-Vivo Secretory Phospholipase A2."

"This is a ground breaking study that demonstrates the possibility of inhibiting the enzyme responsible for surfactant catabolism in critically ill infants and neonates," stated Dr. De Luca. "Given the results obtained with varespladib we may now start designing studies for its use as a new anti-inflammatory therapy in conditions that do not have clearly efficacious therapies. Sparing endogenous surfactant and reducing inflammation using varespladib may be really helpful given the high mortality and morbidity of such conditions."  

The aim of the study was to test varespladib efficacy in an ex-vivo model of direct endotracheal administration in various types of neonatal acute lung injury. The study found that varespladib efficaciously inhibits sPLA2 in an ex-vivo model of direct administration. This might have important anti-inflammatory effects and spare surfactant from its catabolism.

About European Academy of Pediatric Societies

The EAPS is a partnership between the European Academy of Pediatrics, the European Society for Pediatric and Neonatal Intensive Care and the European Society for Pediatric Research. The EAPS Congress combin
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
4. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
5. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. CryoCor Receives FDA Approval for Right Atrial Flutter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Department of,Justice announced today that it will not ... (CRC) to develop and publicize model contract language,for ... Department said,the language is not likely to be ... in contract negotiations, potentially reducing costs,and shortening the ...
Cached Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:4/18/2014)... one of your worst memories? How did it make ... during a negative personal experience, such as how sad ... to emotional distress, especially when you can,t stop thinking ... up, thinking about the context of the memories, rather ... effective way to alleviate the negative effects of these ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... published in the April issue of Immunity , ... for Medical Research, says it,s time to take a ... treating sepsis, which kills millions worldwide every year, ... molecules released into the bloodstream to fight an injury ... necessary for maintaining good health without inflammation, wounds ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Hepatitis ... C Relapsers and Nonresponders, KENILWORTH, N.J., Nov. 15 ... European Commission on,October 30 approved 48-week standard-dose PEGINTRON(TM) (peginterferon,alfa- 2b, ... mg,daily) combination therapy for retreating adult patients with chronic,hepatitis C ...
... largely on children entering school ready to learn, and ... children for school entry. A new study finds that ... for school, suggesting that intervention could help boost readiness ... Laval University, the University of Montreal, and the University ...
... some prescriptions , , WEDNESDAY, Nov. 14 (HealthDay News) -- ... allow certain drugs to be sold by pharmacists without ... to arguments for and against the proposal by representatives ... at the day,s end, the FDA officials said they ...
... Response Genetics, Inc.,(Nasdaq: RGDX ) a company ... cancer, today announced its consolidated financial results for,the ... September 30, 2007. "The third quarter of ... physician and investment communities," said Kathleen Danenberg,President and ...
... Dragon Pharmaceutical Inc.,(TSX: DDD; OTC BB: DRUG; BBSE: ... and nine months ended September 30, 2007, showing ... antibiotic business. Meanwhile,the Company also announced the sale ... a separate press release. Highlights for the ...
... Holdings, Inc. (the,"Company") today announced its operating results for ... Three Months Ended September 30, 2007 Net Revenues ... for the three months,ended September 30, 2007, increased by ... Patient days increased by 289 during the 2007 period.,During ...
Cached Medicine News:Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 2Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 3Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 4Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 5Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 6Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 7Health News:PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy 8Health News:Environment plays key role in children's readiness for school 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 2Health News:Response Genetics Reports Third Quarter 2007 Financial Results 3Health News:Response Genetics Reports Third Quarter 2007 Financial Results 4Health News:Response Genetics Reports Third Quarter 2007 Financial Results 5Health News:Response Genetics Reports Third Quarter 2007 Financial Results 6Health News:Response Genetics Reports Third Quarter 2007 Financial Results 7Health News:Response Genetics Reports Third Quarter 2007 Financial Results 8Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 2Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 3Health News:Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 2Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 3Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 4Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 5Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 6Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 7Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 8Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 9Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 10Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 11Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 12Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 13Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 14Health News:LifeCare Holdings, Inc. Announces Third Quarter Results 15
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: